Linking inflammation and coagulation: Novel drug targets to treat organ ischemia

Current Opinion in Anaesthesiology

Volumn 24, Issue 4, 2011, Pages 375-380

  Jennewein, Carla ^a   Paulus, Patrick ^a   Zacharowski, Kai ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

B 15 42; cardiovascular surgery; thrombin

Indexed keywords

FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE B; HEPARIN; HIRUDIN; HIRULOG; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN INHIBITOR;

ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN ISCHEMIA; CARDIOVASCULAR SURGERY; CELL MIGRATION; HUMAN; INFARCTION; INFLAMMATION; ISCHEMIA; LEUKOCYTE; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPARIN; HUMANS; INFLAMMATION; ISCHEMIA; RECEPTOR, PAR-1; THROMBIN;

EID: 79960698372     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3283489ac0     Document Type: Article

References (68)

1. Loubele ST, ten Cate H, Spronk HM. Anticoagulant therapy in critical organ ischaemia/reperfusion injury. Thromb Haemost 2010; 104:136-142.
2. Cassie S, Masterson MF, Polukoshko A, et al. Ischemia/reperfusion induces the recruitment of leukocytes from whole blood under flow conditions. Free Radic Biol Med 2004; 36:1102-1111. (Pubitemid 38479864)
3. Morrison H, McKee D, Ritter L. Systemic neutrophil activation in a mouse model of ischemic stroke and reperfusion. Biol Res Nurs 2011; 13:154-163.
4. Kobayashi A, Imamura H, Isobe M, et al. Mac-1 (CD11b/CD18) and intercellular adhesion molecule-1 in ischemia-reperfusion injury of rat liver. Am J Physiol Gastrointest Liver Physiol 2001; 281:G577-G585.
5. Jennewein C, Tran N, Paulus P, et al. Novel aspects of fibrin(ogen) fragments in the course of inflammation. Mol Med 2011. (Epub, PMID: 21210072
6. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109:2698-2704. (Pubitemid 38737913)
7. Chu AJ. Blood coagulation as an intrinsic pathway for proinflammation: a mini review. Inflamm Allergy Drug Targets 2010; 9:32-44.
8. Flick MJ, LaJeunesse CM, Talmage KE, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 2007; 117:3224-3235. (Pubitemid 350096980)
9. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007; 204:1999-2008. (Pubitemid 47236333)
10. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204:571-582. (Pubitemid 46457080)
11. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004; 113:1596-1606. (Pubitemid 39071683)
12. Altieri DC. Regulation of leukocyte-endothelium interaction by fibrinogen. Thromb Haemost 1999; 82:781-786.
13. Iba T, Kidokoro A, Fukunaga M, et al. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005; 23:25-29. (Pubitemid 40083023)
14. Fareed J, Hoppensteadt DA, Leya F, et al. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998; 44:1845-1853. (Pubitemid 28368905)
15. Lee ME, Kweon SM, Ha KS, et al. Fibrin stimulates microfilament reorganization and IL-1beta production in human monocytic THP-1 cells. Mol Cells 2001; 11:13-20.
16. Lee ME, Rhee KJ, Nham SU. Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages. Mol Cells 1999; 9:7-13. (Pubitemid 129620070)
17. Petzelbauer P, Zacharowski PA, Miyazaki Y, et al. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005; 11:298-304. (Pubitemid 40460558)
18. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55:552-559. (Pubitemid 23060844)
19. Boisclair MD, Lane DA, Philippou H, et al. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F12. Thromb Haemost 1993; 70:253-258. (Pubitemid 23222479)
20. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993; 70:259-262. (Pubitemid 23222480)
21. Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 2010; 106:360-368.
22. Gruenwald CE, Manlhiot C, Crawford-Lean L, et al. Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery. J Extra Corpor Technol 2010 42: 9-19.
23. Nurden AT, Nurden P, Sanchez M, et al. Platelets and wound healing. Front Biosci 2008; 13:3532-3548. (Pubitemid 351594702)
24. Untch BR, Jeske WP, Schwartz J, et al. Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Clin Appl Thromb Hemost 2008; 14:141-148. (Pubitemid 351364023)
25. Yi Q, Jing P, Xiaodong Z, et al. Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients with HIT. Clin Appl Thromb Hemost 2010 16: 251-260.
26. Gorman RC, Ziats N, Rao AK, et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 111:1-11; discussion: 11-12.
27. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82:3350-3357. (Pubitemid 23356706)
28. Spanier T, Oz M, Levin H, et al. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 1996; 112:1090-1097. (Pubitemid 26339283)
29. Paramo JA. Prothrombin fragments in cardiovascular disease. Adv Clin Chem 2010; 51:1-23.
30. Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003; 101:4355-4362. (Pubitemid 36857799)
31. Parolari A, Mussoni L, Frigerio M, et al. Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery. J Thorac Cardiovasc Surg 2005; 130:303-308. (Pubitemid 41074157)
32. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385-391. (Pubitemid 20271869)
33. Farivar AS, Delgado MF, McCourtie AS, et al. Crosstalk between thrombosis and inflammation in lung reperfusion injury. Ann Thorac Surg 2006; 81:1061-1067. (Pubitemid 43247689)
34. Erlich JH, Boyle EM, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000; 157:1849-1862.
35. Chen B, Cheng Q, Yang K, et al. Thrombin mediates severe neurovascular injury during ischemia. Stroke 2010; 41:2348-2352.
36. Mattsson C, Sarich TC, Carlsson SC. Mechanism of action of the oral direct thrombin inhibitor ximelagatran. Semin Vasc Med 2005; 5:235-244. (Pubitemid 41243658)
37. Marty I, Peclat V, Kirdaite G, et al. Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest 2001; 107:631-640. (Pubitemid 32205184)
38. Babuin L, Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 2010; 6:813-819.
39. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:925-931; discussion: 31. (Pubitemid 38271062)
40. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131:533-539.
41. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83:572-577. (Pubitemid 46156924)
42. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359:294-302.
43. Khan MM, Gikakis N, Miyamoto S, et al. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass. Ann Thorac Surg 1999; 68:473-478. (Pubitemid 29521096)
44. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358:784-793. (Pubitemid 351284456)
45. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358:771-783. (Pubitemid 351284455)
46. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-2331. (Pubitemid 351749156)
47. Mouton R, Finch D, Davies I, et al. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 2008; 371:475-482. (Pubitemid 351200595)
48. Junge CE, Sugawara T, Mannaioni G, et al. The contribution of proteaseactivated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A 2003; 100:13019-13024. (Pubitemid 37340018)
49. Sevastos J, Kennedy SE, Davis DR, et al. Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. Blood 2007; 109:577-583. (Pubitemid 46105956)
50. Pawlinski R, Tencati M, Hampton CR, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 2007; 116:2298-2306. (Pubitemid 350100336)
51. Strande JL, Hsu A, Su J, et al. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol 2007; 102:350-358. (Pubitemid 46909714)
52. Antoniak S, Rojas M, Spring D, et al. Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2010 30: 2136-2142.
53. Napoli C, De Nigris F, Cicala C, et al. Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol Heart Circ Physiol 2002; 282:H2004-H2010. (Pubitemid 34663006)
54. Jiang R, Zatta A, Kin H, et al. PAR-2 activation at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts. Am J Physiol Heart Circ Physiol 2007; 293:H2845-H2852. (Pubitemid 350106507)
55. Adams RA, Passino M, Sachs BD, et al. Fibrin mechanisms and functions in nervous system pathology. Mol Interv 2004; 4:163-176 (Pubitemid 38960845)
56. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010; 30:10-16.
57. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients? Why, how, and when. Stroke 2009; 40:1549-1552.
58. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799-1809. (Pubitemid 41434626)
59. Chandler WL, Velan T. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coagul Fibrinolysis 2004; 15:583-591. (Pubitemid 39372475)
60. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study - a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000; 283:2395-2403. (Pubitemid 30257538)
61. Hennerici MG, Kay R, Bogousslavsky J, et al. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: A randomised controlled trial. Lancet 2006; 368:1871-1878. (Pubitemid 44794528)
62. Levy DE, del Zoppo GJ, Demaerschalk BM, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 h of stroke onset in the ancrod stroke program. Stroke 2009; 40:3796-3803.
63. Adhami F, Liao G, Morozov YM, et al. Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy. Am J Pathol 2006; 169:566-583. (Pubitemid 44156315)
64. Roesner JP, Petzelbauer P, Koch A, et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med 2009; 37:598-605.
65. Gröger M, Pasteiner W, Ignatyev G, et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One 2009; 4:e5391.
66. Atar D, Petzelbauer P, Schwitter J, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009; 53:720-729.
67. Hallen J, Petzelbauer P, Schwitter J, et al. Impact of time to therapy and presence of collaterals on the efficacy of FX06 in acute ST elevation myocardial infarction: a substudy of the F.I.R.E., the Efficacy of FX06 in the prevention of myocardial reperfusion injury trial. EuroIntervention 2010; 5:946-952.
68. Hallen J, Atar D, Serebruany V. Effects of FX06 in vitro on platelet, coagulation, and fibrinolytic biomarkers in volunteers and patients with documented coronary artery disease. Am J Ther 2009. doi:10.1097/MJT. 0b013e3181b0a6ff.